Adimab Announces Successful Resolution of Lawsuit Brought Against LinkedUp Bioscience and Tianti Biotherapeutics
In return for undisclosed consideration to Adimab, Adimab has withdrawn its claims that the LinkedUp parties misappropriated Adimab technology or breached any confidentiality agreement, and the LinkedUp parties shall have the unfettered right to continue using their technology as it exists today.
- In return for undisclosed consideration to Adimab, Adimab has withdrawn its claims that the LinkedUp parties misappropriated Adimab technology or breached any confidentiality agreement, and the LinkedUp parties shall have the unfettered right to continue using their technology as it exists today.
- Similarly, LinkedUp and its related parties have withdrawn their counterclaims, including unfair and deceptive trade practices, intentional interference with business relationships, and infliction of emotional distress.
- Our partners know that we bring unique technology and expertise to our efforts,” added Philip T. Chase, Chief Executive Officer of Adimab.
- Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.